Allogene Therapeutics Inc (NAS:ALLO)
$ 2.14 -0.05 (-2.28%) Market Cap: 459.18 Mil Enterprise Value: 269.53 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 37/100

Allogene Therapeutics Inc to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the American Society of Hematology Annual Meeting Transcript

Dec 13, 2021 / 09:30PM GMT
Release Date Price: $14.11 (-21.74%)
Operator

Hello. Thank you for standing by, and welcome to Allogene Therapeutics ASH 2021 Conference Call. (Operator Instructions) Please be aware that today's conference call is being recorded.

I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.

Christine Cassiano
Allogene Therapeutics, Inc. - Chief Communications Officer

Thank you, operator, and welcome to all who have joined this call. Earlier today, Allogene issued 2 press releases discussing data on our ALPHA, ALPHA2 and UNIVERSAL trials presented at this year's American Society of Hematology Annual Meeting in Atlanta. These press releases, today's webcast and corresponding slides are available on our website. We're looking forward to discussing the latest results from these programs as we progress toward our goal of making AlloCAR T therapy a reality for cancer patients.

On the call today to review the data presented at ASH are Dr. David Chang, President and Chief Executive Officer; and Dr. Rafael Amado, Executive Vice

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot